SCHEMBL4717878

SCHEMBL4717878

CC(C)(C)OC(=O)N1CCN(S(=O)(=O)c2cc(C(=O)O)c(Cl)cc2Cl)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.62
KMT2A Q03164 3/20 0.62
LMNA P02545 2/20 0.62
ALDH1A1 P00352 1/20 0.62
TGM2 P21980 11/20 0.55
F13A1 P00488 9/20 0.55
TGM1 P22735 6/20 0.55
TGM3 Q08188 1/20 0.55
TDP1 Q9NUW8 1/20 0.51
MAPT P10636 1/20 0.48
TSHR P16473 1/20 0.47
CNR1 P21554 1/20 0.47
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA3 P07451 1/20 0.46
CA4 P22748 1/20 0.46
CA6 P23280 1/20 0.46
CA5A P35218 1/20 0.46
CA7 P43166 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL392870 0.83 KMT2A (0.64) MEN1KMT2ATGM2F13A1TGM1
SCHEMBL2826209 0.82 TDP1 (0.64) MEN1KMT2ALMNAALDH1A1TGM2
SCHEMBL19683494 0.80 KMT2A (0.74) MEN1KMT2ALMNAALDH1A1TDP1
SCHEMBL29060789 0.80 MAPT (0.73) MEN1KMT2AALDH1A1TGM2F13A1
SCHEMBL4760580 0.79 MEN1 (0.97) MEN1KMT2ALMNAALDH1A1TDP1
SCHEMBL4761472 0.79 MEN1 (0.91) MEN1KMT2ALMNAALDH1A1TDP1
SCHEMBL22405787 0.78 TGM2 (0.64) MEN1KMT2ALMNAALDH1A1TGM2
SCHEMBL4716208 0.77 MEN1 (1.00) MEN1KMT2ALMNAALDH1A1TDP1
SCHEMBL4716285 0.77 MEN1 (1.00) MEN1KMT2ALMNAALDH1A1TDP1
SCHEMBL4274049 0.77 STS (0.60) TGM2F13A1TGM1TGM3CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615904-B1 SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS ASTRAZENECA AB (SE) 2008-02-27 EP disclosed
US-20070021606-A1 Therapeutic compounds ASTRAZENECA AB (SE) 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021606-A1 Therapeutic compounds GRIN1, GRIN3A, GRM2 MEN1 4633/4885KMT2A 3726/4885LMNA 4722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.